Springer Medicine

A man with type 2 diabetes and IgG4-related kidney disease developed bullous pemphigoid. DPP4 inhibitor treatment, which also correlated with changes in renal function, was discontinued.

A premature infant with extensive central nervous system injury from recurrent E. coli infection, requiring non-traditional methods to identify and clear the infection.

Intralesional treatment with the oncolytic virus talimogene laherparepvec led to a complete local response in a patient with oral mucosal melanoma who was ineligible for other anticancer therapies.

Cladribine tablets are approved for relapsing multiple sclerosis, but patients may have many questions about switching to a short-course treatment. Here are the answers.

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.

An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.